Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
- Poster presentation
- Open Access
Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
Journal for ImmunoTherapy of Cancer volume 1, Article number: P51 (2013)
Aim of this study was to assess whether specified immune cells subsets at baseline could help identifying patients with longer progression-free survival (PFS) in a clinical trial of metastatic breast cancer patients receiving docetaxel±vaccine.
We applied flow-cytometer analysis of PBMCs harvested before treatment from patients (n=43) enrolled in a small randomized phase II study of docetaxel alone (n=20) or in combination with PANVACTM-V (Vaccinia) and PANVACTM-F (Fowlpox) encoding for the tumor-associated antigens CEA and MUC-1, along with a TRIad of COstimulatory Molecules (B7-1, ICAM-1, and LFA-3; called TRICOM) (n=23). As criterion 1, we analyzed the frequency standard immune subsets, i.e. CD4, CD8, NK, Treg, MDSC, and their ratios. As criterion 2, we measured phenotypes indicating immune function, i.e. central memory T lymphocytes, T cells expressing at ≥2 suppressive markers among CTLA-4, PD1, TIM3, and 2B4, CD49d- Tregs, lin- MDSCs, CD56brCD16- NK cells, and their ratios. An immunoscore was generated based on the analysis of tertiles. Log-Rank Kaplan Meier analysis was applied to evaluate differences of PFS between patients with low- and- high immunoscore.
The predetermined immunoscore based on phenotypes indicating immune function allowed discrimination between patients with longer PFS vs. shorter PFS in vaccine plus docetaxel arm (p<0.001, HR=0.049) but not in docetaxel alone arm (p=0.875; HR=0.926).
The calculation of an immunoscore based on a flow-cytometer screening of predetermined immune subsets indicating immune function from PBMCs before treatment could be a potential useful tool for the identification of patients that can benefit from combination immunotherapy.
About this article
Cite this article
Grenga, I., Donahue, R.N., Gulley, J.L. et al. Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival. j. immunotherapy cancer 1, P51 (2013). https://doi.org/10.1186/2051-1426-1-S1-P51
- Breast Cancer Patient
- Metastatic Breast Cancer
- Immune Function
- Metastatic Breast